惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

U
Unit 42
F
Fortinet All Blogs
Martin Fowler
Martin Fowler
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
IT之家
IT之家
Blog — PlanetScale
Blog — PlanetScale
罗磊的独立博客
V
V2EX
Vercel News
Vercel News
Apple Machine Learning Research
Apple Machine Learning Research
J
Java Code Geeks
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
T
Tailwind CSS Blog
I
InfoQ
Engineering at Meta
Engineering at Meta
WordPress大学
WordPress大学
S
SegmentFault 最新的问题
H
Help Net Security
腾讯CDC
D
Docker
P
Proofpoint News Feed
GbyAI
GbyAI
博客园 - 三生石上(FineUI控件)
aimingoo的专栏
aimingoo的专栏

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Tra...
2026-05-08 · via All Articles on Seeking Alpha

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT

Company Participants

Thomas Leggett - Chief Financial Officer
Ian Smith - CEO & Director
Barry Ticho - Chief Medical Officer
Jason Hoitt - Chief Patient Officer

Conference Call Participants

Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Sumant Kulkarni - Canaccord Genuity Corp., Research Division
John Cox - Jefferies LLC, Research Division
Laura Chico - Wedbush Securities Inc., Research Division
Marc Goodman - Leerink Partners LLC, Research Division
Yaron Werber - TD Cowen, Research Division
Thomas Shrader - BTIG, LLC, Research Division
Joseph Stringer - Needham & Company, LLC, Research Division
Adam Ferrari - JPMorgan Chase & Co, Research Division
Yatin Suneja - Guggenheim Securities, LLC, Research Division
Guofang Li - Wolfe Research, LLC

Presentation

Operator

Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to Stoke Therapeutics First Quarter 2026 Business and Financial Update Conference Call. [Operator Instructions]

I would now like to turn the conference over to Thomas Leggett, Chief Financial Officer. You may begin.

Thomas Leggett
Chief Financial Officer

Good afternoon, and welcome to Stoke Therapeutics first quarter 2026 business update conference call. I'm Thomas Leggett, Chief Financial Officer of Stoke Therapeutics. Joining me on today's call are Ian Smith, our Chief Executive Officer; Dr. Barry Ticho, Chief Medical Officer; and Jason Hoitt, Chief Patient Officer. As a reminder, today's webcast presentation is available in the Investors section of our website. This webcast is being recorded and will be available for replay later this evening.

Before we begin, please note that today's discussion includes forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Please refer to our filings with the SEC for additional information.

With that, I